Your browser doesn't support javascript.
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study.
Nontawong, Nuttakant; Siripongboonsitti, Taweegrit; Tawinprai, Kriangkrai; Boonpratoom, Mana; Krailassiri, Nawin; Boonkhum, Chayaporn; Soonklang, Kamonwan; Poovorawan, Yong; Mahanonda, Nithi.
  • Nontawong N; Department of Medicine, Prachathiput Hospital, Pathum Thani, Thailand.
  • Siripongboonsitti T; Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand. Taweegrit.sir@cra.ac.th.
  • Tawinprai K; Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand. Taweegrit.sir@cra.ac.th.
  • Boonpratoom M; Division of Infectious Diseases, Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Krailassiri N; Naungsau Hospital, Pathum Thani, Thailand.
  • Boonkhum C; Naungsau Hospital, Pathum Thani, Thailand.
  • Soonklang K; Department of Medicine, Prachathiput Hospital, Pathum Thani, Thailand.
  • Poovorawan Y; Center of Learning and Research in Celebration of HRH Princess Chulabhorn 60th Birthday Anniversary, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Mahanonda N; Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Ann Clin Microbiol Antimicrob ; 21(1): 51, 2022 Nov 19.
Article in English | MEDLINE | ID: covidwho-2139308
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe COVID-19.

OBJECTIVE:

This case-control study evaluated transfusion efficacy and adverse events with high-titer (≥ 1320) COVID-19 convalescent plasma compared with standard care alone in severe COVID-19 pneumonia.

RESULTS:

Among 107 severe COVID-19 patients, 55 received CPT plus standard care, and 52 received standard care alone. All-cause mortality was 15.3% in the CPT group compared with 85.4% in the standard care group (p < 0.001). Univariate and multivariate analyses revealed reduced mortality with CPT (HR 0.14; 95% CI 0.07-0.31; p < 0.001 and HR 0.26; 95% CI 0.08-0.79; p = 0.018, respectively). CPT resulted in decreased use of mechanical ventilation, duration of supplemental oxygen, and high-flow oxygen requirement. Clinical and radiological outcomes improved.

CONCLUSIONS:

Immediate high neutralizing antibody titer CPT is safe and reduces mortality in early developed severe COVID-19 patients. The benefit of CPT in the early course of illness is challenging and requires additional study. Trial registration Thai clinical trials registry (TCTR) no. 20220101003.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Ann Clin Microbiol Antimicrob Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S12941-022-00542-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Ann Clin Microbiol Antimicrob Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S12941-022-00542-2